The oral bioavailability of etretinate (ET) and its presystemic loss due to pulmonary extraction were studied in the rat. The oral bioavailability was found to be 15%. The percentage of a dose of ET escaping pulmonary extraction was estimated to be 49%. These data suggest substantial presystemic loss of ET, including significant extraction by the lungs.
|Original language||English (US)|
|Number of pages||4|
|Journal||Research Communications in Chemical Pathology and Pharmacology|
|State||Published - 1988|